ABNewswire - Press Release Distribution Service

Friday, February 20, 2026

Interior Painting Contractor in Philadelphia, PA, Observes Spring Surge as Homeowners Seek Refreshed Living Spaces

Philadelphia, PA - As temperatures warm and daylight extends, Beauty Walls and Floor is experiencing the annual spring surge that owner Sviat Oleksyuk has come to anticipate each year. The seasonal shift brings a wave of homeowners eager to refresh their living spaces, transforming interiors that may have been neglected during the darker winter months.

"Summer is the best, as well as spring time, when people get inspired with new ideas to improve their life," says Sviat Oleksyuk, interior painting contractor in Philadelphia, PA. This inspiration translates into increased demand for home improvement projects as families emerge from what Oleksyuk describes as the challenging winter season, particularly the slow months of January and February. The renewed energy of spring creates ideal conditions for homeowners to reimagine their spaces.

The spring season aligns perfectly with Beauty Walls and Floor's core philosophy of creating comfortable, healthy living environments. Sviat Oleksyuk, who specializes in residential painting in Philadelphia, PA, emphasizes the importance of living spaces that promote well-being. "No dust, no germs, no mold - healthy environment, in addition customer's favorite colors for better mood," Oleksyuk explained, highlighting how fresh paint contributes to both physical health and emotional wellness.

Beauty Walls and Floor offers comprehensive interior solutions, with Sviat Oleksyuk providing wall painting services in Philadelphia, PA alongside complete room transformations. His expertise extends to ceiling painting in Philadelphia, PA, ensuring every surface contributes to the overall beauty and comfort of a home. Oleksyuk remains personally present at every job site, serving as the sole point of contact to address customer concerns and solve problems immediately.

Whether preparing a house for sale or customizing a new property for incoming owners, Beauty Walls and Floor brings a decade of experience to every project. Homeowners looking to capitalize on spring inspiration can visit https://beautywallsandfloor.com/ to explore services and connect with a contractor who understands the transformative power of a beautifully painted home.

Media Contact
Company Name: Beauty Walls and Floor | Painting company in Philadelphia PA
Contact Person: Sviat Oleksyuk
Email:Send Email
Phone: +1 267 262 1602
Address:900 N Broad St Num 144
City: Philadelphia
State: PA 19130
Country: United States
Website: https://beautywallsandfloor.com/

Motorcycle Accident Lawyer in Vero Beach, FL, Notes Left-Turn Collisions Remain Leading Cause of Serious Rider Injuries

Vero Beach, FL - Left-turn collisions continue to represent the most dangerous and frequently occurring type of motorcycle crash in Indian River County, according to analysis from Graves Thomas Injury Law Group in Vero Beach. These intersection accidents typically occur when drivers turning left misjudge an approaching motorcycle's speed or fail to see the rider entirely, resulting in catastrophic impacts that often cause life-altering injuries or fatalities.

Joseph H. Graves, Founder and CEO of Graves Thomas Injury Law Group and a motorcycle accident lawyer in Vero Beach, FL, explains that despite motorcycles having the full right of way, visibility challenges and driver inattention create ongoing risks. "We see the same pattern repeatedly along US-1, SR-60, and A1A—drivers make left turns directly into the path of oncoming motorcyclists who have done nothing wrong," Graves states. "These crashes are preventable, yet they continue to cause devastating injuries to riders throughout our community."

The firm's attorneys, who are themselves experienced motorcycle riders, bring unique insight into how these accidents occur and why traditional driver assumptions about speed and distance fail when motorcycles are involved. As a personal injury attorney in Vero Beach, FL with over two decades of experience, Graves emphasizes that motorcycle accident cases require attorneys who understand riding dynamics, braking capabilities, and the split-second decisions riders must make.

Left-turn collisions frequently result in severe orthopedic injuries including femur fractures, pelvic fractures, and traumatic injuries requiring extensive surgery and rehabilitation. In the most tragic cases, the firm serves as a wrongful death attorney in Vero Beach, FL for families who have lost loved ones to preventable crashes caused by driver negligence.

As an experienced brain injury lawyer in Vero Beach, FL, the Graves Thomas team handles complex cases involving severe neurological trauma, as helmeted and unhelmeted riders alike can suffer devastating injuries in high-impact intersection collisions.

For riders injured in left-turn collisions or other motorcycle accidents in Vero Beach and Indian River County, Graves Thomas Injury Law Group offers consultations to discuss legal options. Visit https://www.gravesthomas.com/ or call today to speak with attorneys who ride and understand what you're facing.

Media Contact
Company Name: Graves Thomas Injury Law Group Vero Beach
Contact Person: Joseph H. Graves
Email:Send Email
Phone: +1 (772) 247-6021
Address:2651 20th St
City: Vero Beach
State: FL 32960
Country: United States
Website: https://www.gravesthomas.com/

Bipolar Depression Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Bipolar Depression Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the Bipolar Depression Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bipolar Depression Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Bipolar Depression Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight

Key Takeaways from the Bipolar Depression Pipeline Report

On February 17, 2026- University of Sao Paulo initiated a study is to evaluate the efficacy of combining lacosamide as an augmentation treatment to first- or second-line medication treatments in moderate to severe major depressive episodes of treatment-resistant BD I and II (failure of at least two adequate treatments during the current episode). The main hypothesis of the study is that lacosamide produces a greater reduction in depression scores compared to a placebo treatment and that both groups will exhibit similar rates of side effects and adverse events. We will conduct a double-blind, randomized, parallel-group pilot study, comparing the enhancement of the treatment that patients had been using with lacosamide and placebo, over a duration of 12 weeks. Forty subjects aged between 18 and 65 years with a diagnosis of BD (I or II) in a moderate or severe major depressive episode, despite the use of first- or second-line treatments, will be selected.
On February 04, 2026- AbbVie conducted a Study doctors put participants in 1 of 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 380 Participants ages 10-17 years with bipolar I disorder will be enrolled in approximately 60 sites worldwide.
On February 03, 2026- Xenon Pharmaceuticals Inc. announced a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
DelveInsight’s Bipolar Depression Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Bipolar Depression treatment.
The leading Bipolar Depression Companies such as NRx Pharmaceuticals Inc., Autobahn Therapeutics, Sunovion Pharmaceuticals Inc., and others.
Promising Bipolar Depression Therapies such as KarXT, AL001, RP5063, RAP 219, NRX-101, LB 102, Aripiprazole 2-month injectable, ABBV-932, ABX-002, ALTO-100, CB03-154, 4MT 2001 and others.

Want to know which companies are leading innovation in Bipolar Depression? Dive into the full pipeline insights @ Bipolar Depression Clinical Trials Assessment

The Bipolar Depression Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Bipolar Depression Pipeline Report also highlights the unmet needs with respect to the Bipolar Depression.

Bipolar Depression Overview

Bipolar depression is a phase of bipolar disorder characterized by prolonged periods of low mood, loss of interest or pleasure in activities, fatigue, sleep disturbances, feelings of worthlessness, difficulty concentrating, and sometimes thoughts of death or suicide. It occurs in individuals diagnosed with either Bipolar I Disorder or Bipolar II Disorder and alternates with episodes of mania or hypomania. Unlike major depressive disorder, bipolar depression is part of a cyclical mood condition, meaning depressive episodes are interspersed with elevated or irritable mood states.

Bipolar Depression Emerging Drugs Profile

NRX-101: NRx Pharmaceuticals, Inc.

NRX-101 is a fixed-dose combination of D-Cycloserine and Lurasidone. NRX-101 is part of NRx Pharma’s investigational medicine regimen of NRX-100 (ketamine) and NRX-101. If approved by the US Food and Drug Administration (FDA) and other health-regulatory agencies, would be the first medicine regimen to treat Severe Bipolar Depression in Patients with Acute Suicidal Ideation and Behavior (ASIB). NRX-101 is a patented, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator at certain dosage ranges; and Lurasidone, a 5-HT2a receptor antagonist. The FDA has granted the combination therapy a Breakthrough Therapy Designation (BTD) for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB), after initial stabilization with ketamine or other effective therapy. Currently the drug is in Phase III trial for Bipolar Depression.

ABX-002: Autobahn Therapeutics

ABX-002 is a potent and selective, brain-boosting TRβ agonist that is anticipated to enhance serotonin activity and elicit a brain bioenergetic effect in the brains of people suffering from MDD. Evidence suggests that a brain-targeted thyromimetic such as ABX-002 may, in a more selective fashion, evoke favorable thyroid hormone pharmacology in the CNS, while simultaneously eliminating the peripherally-mediated side effects of synthetic thyroid hormone (i.e., cardiac effects and effects on the thyroid hormone axis). Currently, the drug is in Phase I stage of its development for the treatment of Bipolar Depression.

If you’re tracking ongoing Bipolar Depression Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Bipolar Depression Treatment Drugs

The Bipolar Depression Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Bipolar Depression with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bipolar Depression Treatment.
Bipolar Depression Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Bipolar Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bipolar Depression market.

Bipolar Depression Companies

NRx Pharmaceuticals Inc., Autobahn Therapeutics, Sunovion Pharmaceuticals Inc., and others.

Bipolar Depression Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Bipolar Depression Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Bipolar Depression Pipeline Report covers it all – check it out now @ Bipolar Depression Market Drivers and Barriers, and Future Perspectives

Scope of the Bipolar Depression Pipeline Report

Coverage- Global
Bipolar Depression Companies- NRx Pharmaceuticals Inc., Autobahn Therapeutics, Sunovion Pharmaceuticals Inc., and others.
Bipolar Depression Therapies- KarXT, AL001, RP5063, RAP 219, NRX-101, LB 102, Aripiprazole 2-month injectable, ABBV-932, ABX-002, ALTO-100, CB03-154, 4MT 2001 and others.
Bipolar Depression Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Bipolar Depression Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Bipolar Depression Treatment landscape in this detailed analysis @ Bipolar Depression Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Bipolar depression: Overview
Pipeline Therapeutics
Therapeutics Assessment
Bipolar depression– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
NRX-100/NRX-101: NRx Pharmaceuticals, Inc.
Mid Stage Products (Phase II)
ABX-002: Autobahn Therapeutics
Early Stage Products (Phase I/II)
Preclinical and Discovery Stage Products
Inactive Products
Bipolar depression Key Companies
Bipolar depression Key Products
Bipolar depression- Unmet Needs
Bipolar depression- Market Drivers and Barriers
Bipolar depression- Future Perspectives and Conclusion
Bipolar depression Analyst Views
Bipolar depression Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/bipolar-depression-pipeline-insight

Sjogren's Syndrome Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Sjogren’s Syndrome Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Sjogren’s Syndrome pipeline landscape. It covers the Sjogren’s Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sjogren’s Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Sjogren’s Syndrome Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight

Key Takeaways from the Sjogren’s Syndrome Pipeline Report

On February 17, 2026, Immunovant Sciences GmbH announced a phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity.
On February 13, 2026- Janssen Research & Development LLC conducted a study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD). This clinical development program for nipocalimab in SjD includes 2 identical double blind, placebo-controlled studies to evaluate the efficacy, safety, and tolerability of nipocalimab in participants greater than or equal to (>=) 18 years of age with moderate to severe SjD.
On February 12, 2026- Amgen initiated a Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren's Syndrome (SS).
DelveInsight’s Sjogren’s Syndrome Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Sjogren’s Syndrome treatment.
The leading Sjogren’s Syndrome Companies such as Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.
Promising Sjogren’s Syndrome Therapies such as Baricitinib, Hydroxychloroquine, Nipocalimab, HZN-1116, RSLV-132, RO5459072, Lanraplenib, Filgotinib, Tirabrutinib, Belimumab, Iscalimab and others.

Want to know which companies are leading innovation in Sjogren’s Syndrome? Dive into the full pipeline insights @ Sjogren’s Syndrome Clinical Trials Assessment

The Sjogren’s Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Sjogren’s Syndrome Pipeline Report also highlights the unmet needs with respect to the Sjogren’s Syndrome.

Sjogren’s Syndrome Overview

Sjögren’s syndrome is a chronic autoimmune disorder in which the body’s immune system mistakenly attacks its own moisture-producing glands, primarily the salivary and tear glands, leading to persistent dry eyes and dry mouth. Over time, the condition can also affect other organs, including the joints, skin, lungs, kidneys, and nervous system. It may occur alone (primary Sjögren’s syndrome) or alongside other autoimmune diseases such as rheumatoid arthritis or lupus (secondary Sjögren’s syndrome). Common symptoms include eye irritation, difficulty swallowing, fatigue, joint pain, and swollen salivary glands.

Sjogren’s Syndrome Emerging Drugs Profile

VAY736: Novartis

VAY736 (Ianalumab) is a novel, defucosylated, human IgG1/κ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy. The drug is currently in Phase III clinical studies for the treatment of Sjögren’s Syndrome.

Nipocalimab: Johnson & Johnson

IMAAVY is a monoclonal antibody, designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies that underlie generalized myasthenia gravis (gMG) without additional detectable effects on other adaptive and innate immune functions. The investigational monoclonal antibody is designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) auto and alloantibodies potentially without additional detectable effects on other adaptive and innate immune functions. The drugs has also been granted Breakthrough Therapy designation for for Sjögren’s disease by the US FDA. Currently, the drug is in Phase III stage of its development for the treatment of Sjogren’s syndrome.

Allogeneic NK Cells: Artiva Biotherapeutics

AlloNK is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the ADCC effect of mAbs to drive B-cell depletion. AlloNK, as a non-genetically modified, non-targeted NK cell, is designed to utilize a mAb or NK engager for targeting, and therefore can be used in different combinations against different therapeutic targets. Currently, the drug is in Phase II stage of its development for the treatment of Sjogren’s syndrome.

ASP5502: Astellas Pharma Inc.

ASP5502 is an investigational small-molecule drug developed by Astellas Pharma, designed to inhibit the STING (Stimulator of Interferon Genes) pathway, which plays a crucial role in innate immune responses and is implicated in autoimmune conditions like primary Sjögren’s syndrome. By targeting this pathway, ASP5502 aims to modulate the immune system's activity, potentially alleviating the chronic inflammation and glandular dysfunction characteristic of the disease. Notably, ASP5502 was identified through Astellas's innovative use of artificial intelligence in drug discovery, highlighting a modern approach to developing treatments for complex autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Sjogren’s syndrome.

If you’re tracking ongoing Sjogren’s Syndrome Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Sjogren’s Syndrome Treatment Drugs

The Sjogren’s Syndrome Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren’s Syndrome with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren’s Syndrome Treatment.
Sjogren’s Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Sjogren’s Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren’s Syndrome market.

Sjogren’s Syndrome Companies

Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.

Sjogren’s Syndrome Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Sjogren’s Syndrome Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Sjogren’s Syndrome Pipeline Report covers it all – check it out now @ Sjogren’s Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Sjogren’s Syndrome Pipeline Report

Coverage- Global
Sjogren’s Syndrome Companies- Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.
Sjogren’s Syndrome Therapies- Baricitinib, Hydroxychloroquine, Nipocalimab, HZN-1116, RSLV-132, RO5459072, Lanraplenib, Filgotinib, Tirabrutinib, Belimumab, Iscalimab and others.
Sjogren’s Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Sjogren’s Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Sjogren’s Syndrome Treatment landscape in this detailed analysis @ Sjogren’s Syndrome Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Sjogren’s syndrome: Overview
Pipeline Therapeutics
Therapeutic Assessment
Sjogren’s syndrome– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
VAY736: Novartis
Mid Stage Products (Phase II)
Allogeneic NK Cells: Artiva Biotherapeutics
Early Stage Products (Phase I)
ASP5502: Astellas Pharma Inc
Preclinical and Discovery Stage Products
Inactive Products
Sjogren’s syndrome Key Companies
Sjogren’s syndrome Key Products
Sjogren’s syndrome- Unmet Needs
Sjogren’s syndrome- Market Drivers and Barriers
Sjogren’s syndrome- Future Perspectives and Conclusion
Sjogren’s syndrome Analyst Views
Sjogren’s syndrome Key Companies
Appendix

About Us

Bispecific Antibody Competitive Landscape, Analytical Perspective, Therapeutics Assessment, Preclinical and Discovery Stage Products Report 2025

DelveInsight's, "Bispecific antibody Competitive landscape, 2025," report provides comprehensive insights about 180+ companies and 250+ drugs in Bispecific antibody Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Bispecific Antibody Drugs @ https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape

Key Takeaways from the Bispecific Antibody Competitive Landscape Report

On February 19, 2026- Merus B.V. initiated a phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.
On February 18, 2026- Regeneron Pharmaceuticals announced a phase 2 study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin [PLD]), referred to as "combination drugs'.
On February 18, 2026- AstraZeneca initiated a Phase II study evaluating the preliminary efficacy and safety of Volrustomig or Rilvegostomig as monotherapy (MONO) and/or in combination with anticancer agents (COMBO) in participants with advanced hepatobiliary cancer (e.g., HCC, BTC, etc.).
On February 13, 2026- Janssen Pharmaceutical K.K. conducted a phase 1/2 study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001 (NCT03145181) in Phase 1 part and to evaluate the efficacy of teclistamab at RP2D for Japanese participants in Phase 2 part.
On February 13, 2026- Genmab announced a phase 1b/2 trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD; if reached) as well as establish the safety profile of epcoritamab monotherapy and epcoritamab + venetoclax in participants with R/R CLL.
DelveInsight's Bispecific Antibody report depicts a robust space with 180+ active players working to develop 250+ pipeline therapies for Bispecific Antibody treatment.
The leading companies working in the Bispecific Antibody Competitive landscape include Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
Promising Bispecific Antibody Therapies in the various stages of development include SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.

The Bispecific Antibody competitive landscape report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition - deal values trends. The sub-segmentation is described in the Bispecific Antibody report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.

Bispecific Antibody Overview

Immunoglobulins (antibodies [Abs]) are major protein components of the adaptive immune system, directed against foreign compounds and infectious agents. The IgG molecule consists of two light and two heavy chains connected by disulfide bonds; IgG is a monomer with a molecular weight of 146-160 kDa. Antigen-binding centers of Abs are formed by hypervariable regions of heavy and light chains. In the classical point of view, the Ab molecule contains two identical antigen-binding sites (two HL fragments) and is monospecific and bivalent.

Find out more about Bispecific Antibody Analytical Perspective: In-depth Commercial Assessment @ Bispecific Antibody Collaboration Analysis by Companies

Bispecific Antibody Competitive Landscape

The Bispecific Antibody competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Bispecific Antibody Report Assessment

Bispecific Antibody Company Analysis
Bispecific Antibody Therapeutic Assessment
Bispecific Antibody Pipeline Assessment
Inactive drugs assessment
Bispecific Antibody Unmet Needs

Learn more about the emerging Bispecific Antibody Competitive Landscape @ Bispecific Antibody Market Drivers and Barriers, Unmet Needs

Scope of the Bispecific Antibody Report

Coverage- Global
Bispecific Antibody Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
Bispecific Antibody Companies- Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
Bispecific Antibody Therapies- SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin, and others.

Dive deep into rich insights for new drugs for Bispecific Antibody Product Developmental Activities, Visit @ Bispecific Antibody Research and Development Activities

Table of Content

Introduction
Executive Summary
Bispecific antibody: Overview
Bispecific Antibody -Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Therapeutic Assessment
Bispecific antibody: Company and Product Profiles (Marketed Therapies)
Janssen
Amivantamab
Bispecific antibody: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
Akeso
Ivonescimab
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)
IGM Biosciences
Imvotamab
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
MacroGenics
MGD024
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Company Name
Product Name
Drug profiles in the detailed report.....
Inactive Products
Bispecific antibody- Unmet needs
Bispecific antibody - Market drivers and barriers
Appendix

About Us

Neuromyelitis Optica Spectrum Disorder Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Neuromyelitis Optica Spectrum Disorder Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Neuromyelitis Optica Spectrum Disorder pipeline landscape. It covers the Neuromyelitis Optica Spectrum Disorder Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Neuromyelitis Optica Spectrum Disorder Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight

Key Takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report

On February 13, 2026- Hoffmann-La Roche announced a phase III study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.
DelveInsight’s Neuromyelitis Optica Spectrum Disorder Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder treatment.
The leading Neuromyelitis Optica Spectrum Disorder Companies such as Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co. Ltd, Shanghai Xiniao Biotech Co., Ltd. and others.
Promising Neuromyelitis Optica Spectrum Disorder Therapies such as Ravulizumab, B001, Eculizumab, Inebilizumab, MIL62, satralizumab, azathioprine (AZA), NPB-01, JYP0061 and others.

Want to know which companies are leading innovation in Neuromyelitis Optica Spectrum Disorder? Dive into the full pipeline insights @ Neuromyelitis Optica Spectrum Disorder Clinical Trials Assessment

The Neuromyelitis Optica Spectrum Disorder Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Neuromyelitis Optica Spectrum Disorder Pipeline Report also highlights the unmet needs with respect to the Neuromyelitis Optica Spectrum Disorder.

Neuromyelitis Optica Spectrum Disorder Overview

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare, severe autoimmune disease of the central nervous system in which the body’s immune system mistakenly attacks healthy cells in the optic nerves and spinal cord. This condition often leads to episodes of optic neuritis (causing eye pain and vision loss) and transverse myelitis (causing weakness, paralysis, sensory loss, and bladder or bowel dysfunction). Unlike multiple sclerosis, NMOSD is commonly associated with antibodies against aquaporin-4 (AQP4-IgG), which target water channel proteins on astrocytes, leading to inflammation and nerve damage.

Neuromyelitis Optica Spectrum Disorder Emerging Drugs Profile

BAT4406F: Bio-Thera Solutions

BAT4406 is an investigational ADCC-enhanced anti-CD20 mAb candidate in clinical development for the treatment of autoimmune diseases. BAT4406F is currently being evaluated in NMOSD, an orphan indication with an estimated prevalence of 0.5 to 10 per 100,000. BAT4406 is a type I glyco-engineered mAb that binds specifically to CD20 on B-cells, kills the B-cells by CDC, and enhances ADCC effect. B cells have been implicated in the pathogenesis of a number of autoimmune diseases, including the CNS disorders, multiple sclerosis (MS) and NMOSD. Depletion of B-cells could provide meaningful relief for these autoimmune diseases. NMOSD is an autoimmune inflammatory disorder of the central nervous system (CNS) with preferential localization to the optic nerve, spinal cord and brain stem. Patients typically experience bouts of vision loss or blindness, attacks of myelitis with often severe motor impairment including loss of ambulation, sensory disturbances, bowel/bladder dysfunction, and brainstem attacks with characteristic episodes of intractable nausea, vomiting and hiccups. Currently, the drug is in Phase III stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

B001: Shanghai Jiaolian Drug Research and Development Co., Ltd

B001 is a recombinant humanized anti‑CD20 monoclonal antibody developed by Shanghai Jiaolian Drug Research & Development (originating from Shanghai Pharmaceuticals Holding). It works by targeting CD20 on B cells and triggering antibody‑dependent cellular cytotoxicity (ADCC) to deplete autoreactive B cells, a mechanism aligned with current NMOSD treatment goals. Designed for intravenous administration, B001 aims to reduce disease relapses in AQP4‑IgG positive NMOSD through sustained B‑cell suppression. It also shows potential across other autoimmune neurologic conditions and B‑cell malignancies, illustrating a broad therapeutic strategy rooted in targeted immunotherapy. Currently, the drug is in Phase II/III stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

CT103A cells: Nanjing IASO Biotherapeutics

Equecabtagene Autoleucel (Eque-cel) is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, Eque-cel demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses. Currently, the drug is in Phase I stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).

If you’re tracking ongoing Neuromyelitis Optica Spectrum Disorder Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Neuromyelitis Optica Spectrum Disorder Treatment Drugs

The Neuromyelitis Optica Spectrum Disorder Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
Neuromyelitis Optica Spectrum Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.

Neuromyelitis Optica Spectrum Disorder Companies

Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co. Ltd, Shanghai Xiniao Biotech Co., Ltd. and others.

Neuromyelitis Optica Spectrum Disorder Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Neuromyelitis Optica Spectrum Disorder Pipeline Report covers it all – check it out now @ Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers, and Future Perspectives

Scope of the Neuromyelitis Optica Spectrum Disorder Pipeline Report

Coverage- Global
Neuromyelitis Optica Spectrum Disorder Companies- Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co. Ltd, Shanghai Xiniao Biotech Co., Ltd. and others.
Neuromyelitis Optica Spectrum Disorder Therapies- Ravulizumab, B001, Eculizumab, Inebilizumab, MIL62, satralizumab, azathioprine (AZA), NPB-01, JYP0061 and others.
Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Neuromyelitis Optica Spectrum Disorder Treatment landscape in this detailed analysis @ Neuromyelitis Optica Spectrum Disorder Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Neuromyelitis Optica Spectrum Disorder (NMOSD): Overview
Pipeline Therapeutics
Therapeutic Assessment
Neuromyelitis Optica Spectrum Disorder (NMOSD)– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
BAT4406F: Bio-Thera Solutions
Mid Stage Products (Phase II/III)
B001: Shanghai Jiaolian Drug Research and Development Co., Ltd
Early Stage Products (Phase I)
CT103A cells: Nanjing IASO Biotherapeutics
Preclinical and Discovery Stage Products
Inactive Products
Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Companies
Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Products
Neuromyelitis Optica Spectrum Disorder (NMOSD)- Unmet Needs
Neuromyelitis Optica Spectrum Disorder (NMOSD)- Market Drivers and Barriers
Neuromyelitis Optica Spectrum Disorder (NMOSD)- Future Perspectives and Conclusion
Neuromyelitis Optica Spectrum Disorder (NMOSD) Analyst Views
Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Companies
Appendix

About Us

Neuroendocrine Tumors Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Neuroendocrine tumors Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Neuroendocrine tumors pipeline landscape. It covers the Neuroendocrine Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/neuroendocrine-tumors-pipeline-insight

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

On February 12, 2026- University of Michigan Rogel Cancer Center initiated a Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer. Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
On February 12, 2026- Advanced Accelerator Applications conducted a study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to
On February 03, 2026- Novartis Pharmaceuticals announced a study was to evaluate the diagnostic performance of [68Ga]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (HVs).
On February 02, 2026- Jonsson Comprehensive Cancer Center conducted a study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
DelveInsight’s Neuroendocrine Tumors pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Neuroendocrine Tumors treatment.
The leading Neuroendocrine Tumors Companies such as Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.
Promising Neuroendocrine Tumors Pipeline Therapies such as lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Treatment Drugs

Neuroendocrine Tumors Emerging Drugs Profile

CAM2029: Camurus

CAM2029 is a long-acting subcutaneous depot of octreotide under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET) and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen device. Currently, the drug is in the Phase III stage of its development for the treatment of gastroentero pancreatic neuroendocrine tumors.

AlphaMedix: Orano Med

AlphaMedix is a somatostatin receptor targeting peptide radiolabeled with 212Pb. Somatostatin receptors are overexpressed in most neuroendocrine tumors, a heterogeneous group of rare neoplasms that originate from neuroendocrine cells. These neoplasms occur mostly in the gastrointestinal tract and pancreas, but can also occur in other tissues including thymus, lung, and other uncommon sites such as ovaries, heart, and prostate. After the promising results of the Phase I clinical trial launched early 2018, a Phase II was initiated late 2021 to assess the efficacy of Alphamedix in the treatment of neuroendocrine tumors. The study is currently recruiting patients in the US. Currently the drug is in Phase II stage of its clinical development.

Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of its development.

The Neuroendocrine Tumors Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
Neuroendocrine Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market

Access DelveInsight's detailed report now! @ New Neuroendocrine Tumors Drugs

Neuroendocrine Tumors Companies

Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.

Neuroendocrine tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers

Scope of the Neuroendocrine Tumors Pipeline Report

Coverage- Global
Neuroendocrine Tumors Companies- Camurus, Vyriad, Inc., TYK Medicines, Orano Med, Advanced Accelerator Applications, Sinotau Pharmaceutical Group, ITM Solucin GmbH, Molecular Targeting Technologies, Inc., Biotheus Inc., Aadi Bioscience, Inc., TaiRx, Inc. and others.
Neuroendocrine Tumors Pipeline Therapies- lanreotide acetate, Lanreotide (Autogel formulation) and Temozolomide, AlphaMedix, Octreotide LAR, and others.
Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Neuroendocrine Tumors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
RYZ101: RayzeBio, Inc.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Ramucirumab: Eli Lilly and Company
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ADCT-701: ADC Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Neuroendocrine Tumors Key Companies
Neuroendocrine Tumors Key Products
Neuroendocrine Tumors- Unmet Needs
Neuroendocrine Tumors- Market Drivers and Barriers
Neuroendocrine Tumors- Future Perspectives and Conclusion
Neuroendocrine Tumors Analyst Views
Neuroendocrine Tumors Key Companies
Appendix

About Us

Myasthenia Gravis Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Myasthenia Gravis Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Myasthenia Gravis Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight

Key Takeaways from the Myasthenia Gravis Pipeline Report

On February 19, 2026- Alexion Pharmaceuticals, Inc. initiated a phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG).
On February 18, 2026- argenx announced a trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG.
On February 17, 2026- Immunovant Sciences GmbH conducted a phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis.
On February 17, 2026- Vor Biopharma initiated a Phase 3 study with an open-label extension (OLE) to evaluate the efficacy and safety of telitacicept in a global patient population with gMG. The total duration of the study is variable but will include an approximately 4-week screening period, a 24-week double-blind treatment period (Week 0 through Week 24), a 48-week OLE (Week 24 through Week 72), followed by an extended OLE period (E-OLE), and an 8-week end-of-study follow-up period. The E-OLE is variable duration, defined as the period after the 48-week OLE period until telitacicept is approved for MG in the country or the further development in the indication is concluded.
On February 17, 2026- Janssen Research & Development LLC announced a study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age (globally) and 8 to
On February 13, 2026- UCB Biopharma SRL conducted a study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
DelveInsight’s Myasthenia Gravis Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myasthenia Gravis treatment.
The leading Myasthenia Gravis Companies such as Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals, and others.
Promising Myasthenia Gravis Therapies such as NMD670, KYV-101, Inebilizumab, Eculizumab, UCB7665, Efgartigimod, Nipocalimab, TAK-079, RVT-1401 and others.

Want to know which companies are leading innovation in Myasthenia Gravis? Dive into the full pipeline insights @ Myasthenia Gravis Clinical Trials Assessment

The Myasthenia Gravis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Myasthenia Gravis Pipeline Report also highlights the unmet needs with respect to the Myasthenia Gravis.

Myasthenia Gravis Overview

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. In MG, the body's immune system mistakenly attacks receptors on muscle cells, preventing nerve impulses from properly communicating with muscles. This leads to weakness, particularly in muscles that control eye movements, facial expressions, chewing, swallowing, and speaking. However, it can also affect other muscles, including those involved in breathing and limb movements.

Myasthenia Gravis Emerging Drugs

HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.

Batoclimab (HBM9161) is a novel, fully human anti-FcRn mAb blocking FcRn-IgG interactions and accelerating the degradation of autoantibodies. The product has the potential to address a variety of pathogenic IgG-mediated autoimmune diseases. Batoclimab is being evaluated for the treatment of patients with severe autoimmune diseases mediated by pathogenic immunoglobulin G (IgG), including generalized myasthenia gravis (gMG), thyroid eye disease (TED), neuromyelitis optica spectrum disorder (NMOSD) and immune thrombocytopenic purpura (ITP). Phase II study in generalized myasthenia gravis showed that batoclimab can quickly and significantly alleviate patients’ symptoms and improve quality of life. Completed studies demonstrated that batoclimab is well tolerated and can rapidly reduce total IgG in a wide array of pathogenic IgG-mediated autoimmune diseases. Currently, the drug is in Preregistration stage of its development for the treatment of Myasthenia Gravis.

KYV-101: Kyverna Therapeutics

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. Kyverna is currently conducting trials of KYV-101 in patients with lupus nephritis, systemic sclerosis, and myasthenia gravis are in preparation. Currently, the drug is in Phase II stage of its development for the treatment of Myasthenia Gravis.

CABA-201: Cabaletta Bio

CABA-201 is a fully human CD19 chimeric antigen receptor (CAR) T cell therapy containing a 4-1BB co-stimulatory domain. CABA-201 is designed to deeply and transiently deplete CD19-positive B cells following a one-time infusion, which may enable an “immune system reset” with the potential for durable remission off therapy in patients with autoimmune diseases. To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple autoimmune conditions including systemic lupus erythematosus (SLE), myositis, systemic sclerosis (SSc) and generalized myasthenia gravis (gMG). Cabaletta is conducting four RESET™ Phase I/II clinical trials with a total of nine cohorts that can advance simultaneously, employing a similar parallel cohort design and starting dose of 1 x 106 cells/kg without a dose escalation requirement. Currently, the drug is in Phase I/II stage of its development for the treatment of Myasthenia Gravis.

If you’re tracking ongoing Myasthenia Gravis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Myasthenia Gravis Treatment Drugs

The Myasthenia Gravis Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment.
Myasthenia Gravis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market.

Myasthenia Gravis Companies

Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals, and others.

Myasthenia Gravis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Myasthenia Gravis Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Myasthenia Gravis Pipeline Report covers it all – check it out now @ Myasthenia Gravis Market Drivers and Barriers, and Future Perspectives

Scope of the Myasthenia Gravis Pipeline Report

Coverage- Global
Myasthenia Gravis Companies- Harbour BioMed (Guangzhou) Co. Ltd., Kyverna Therapeutics, Cabaletta Bio, Takeda, Hoffmann-La Roche, Immunovant Sciences GmbH, Regeneron Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Momenta Pharmaceuticals, Inc., Amgen, Dianthus Therapeutics, Cartesian Therapeutics, COUR Pharmaceutical Development Company, Inc., Alexion Pharmaceuticals, and others.
Myasthenia Gravis Therapies- NMD670, KYV-101, Inebilizumab, Eculizumab, UCB7665, Efgartigimod, Nipocalimab, TAK-079, RVT-1401 and others.
Myasthenia Gravis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Myasthenia Gravis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Myasthenia Gravis Treatment landscape in this detailed analysis @ Myasthenia Gravis Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Myasthenia Gravis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Myasthenia Gravis – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
HBM9161: Harbour BioMed (Guangzhou) Co. Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
KYV-101: Kyverna Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
CABA-201: Cabaletta Bio
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Myasthenia Gravis Key Companies
Myasthenia Gravis Key Products
Myasthenia Gravis- Unmet Needs
Myasthenia Gravis- Market Drivers and Barriers
Myasthenia Gravis- Future Perspectives and Conclusion
Myasthenia Gravis Analyst Views
Myasthenia Gravis Key Companies
Appendix

About Us

Vinyl Floor Covering Market to Reach USD 64.09 Billion by 2031, Supported by Rigid-Core Adoption and Remodeling Demand

Vinyl Floor Covering Market Size & Trends | Mordor Intelligence

Mordor Intelligence has published a new report on the vinyl floor covering market, offering a comprehensive analysis of trends, growth drivers, and future projections

Vinyl Floor Covering Market Overview

According to Mordor Intelligence, the Vinyl Floor Covering Market Size is expected to grow from USD 43.64 billion in 2025 to USD 46.53 billion in 2026 and is forecast to reach USD 64.09 billion by 2031, registering a CAGR of 6.62% during the forecast period. The steady rise in remodeling projects, wider use of rigid-core formats, and growing preference for low-maintenance flooring solutions are shaping the near-term vinyl floor covering market forecast. Demand remains firm across residential renovation and commercial retrofit projects where durability, moisture resistance, and easy installation are key decision factors. The industry benefits from product formats such as Luxury Vinyl Tile (LVT) and Luxury Vinyl Plank (LVP), which combine aesthetic appeal with performance reliability.

The vinyl floor covering market size is supported by increasing awareness of waterproof and scratch-resistant surfaces, particularly in kitchens, healthcare settings, retail stores, and educational institutions. Manufacturers are also focusing on improving surface textures and emission standards to align with procurement requirements in developed markets. The vinyl floor covering industry benefits from product formats such as Luxury Vinyl Tile (LVT) and Luxury Vinyl Plank (LVP), which combine aesthetic appeal with performance reliability.

Growth Drivers in the Vinyl Floor Covering Market

Shift Toward Rigid-Core Formats (SPC and WPC)

One of the most visible vinyl floors covering market trends is the growing shift toward stone plastic composite and wood plastic composite cores. These rigid-core products offer better dimensional stability and moisture resistance compared to traditional formats. Their waterproof properties make them suitable for basements, bathrooms, and commercial kitchens. Click-lock systems reduce installation time, making them attractive for contractors managing tight schedules. As a result, rigid-core solutions are strengthening their vinyl floor covering market share in both residential and commercial segments.

Growth in Residential Remodeling

Homeowners are investing more in renovation projects rather than relocating, which is supporting vinyl floor covering market growth. Flooring upgrades are among the fastest-return improvements in residential properties. Vinyl’s ability to mimic natural wood and stone at a lower cost has increased adoption among DIY buyers and professional remodelers. Retail distribution channels are expanding their vinyl assortments, offering varied plank sizes, finishes, and wear layers. This broader product availability contributes positively to the overall vinyl floor covering industry outlook.

Rising Preference for Low-Maintenance and Hygienic Surfaces

Healthcare, education, and hospitality facilities prefer seamless and easy-to-clean flooring materials. Vinyl surfaces reduce maintenance downtime and are compatible with modern cleaning standards. Improved low-VOC formulations and phthalate-free plasticizers help manufacturers meet indoor air quality regulations. These features reinforce demand in institutional settings and support long-term vinyl floor covering market forecast stability.

Raw Material Price Sensitivity

PVC resin prices remain influenced by energy and petrochemical inputs. Fluctuations in input costs affect pricing strategies across the vinyl floor covering industry. Manufacturers are working on recycling initiatives and long-term supply contracts to manage cost exposure, but price sensitivity remains a challenge in competitive bidding environments.

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/ja/industry-reports/vinyl-floor-covering-market?utm_source=abnewswire

Vinyl Floor Covering Market Segmentation

By Product Type

Luxury Vinyl Tile (LVT)

Stone Plastic Composite (SPC)

Wood Plastic Composite (WPC)

Luxury Vinyl Plank (LVP)

Sheet Vinyl

Others (VCT, Resilient Vinyl-Backed Rubber Hybrid)

By Installation Method

Self-Adhesive Vinyl Tiles

Glue-Down

Interlocking Vinyl Tiles

Others

By End-User

Residential

Housing & Apartments

Independent Homes

Commercial

Hospitality & Leisure

Retail & Shopping Centers

Healthcare Facilities

Education

Corporate Offices

Public & Government Buildings

Other Commercial Users

By Construction Type

New Construction

Remodeling / Retrofit

By Distribution Channel

B2C / Retail

Home Centers

Specialty Flooring Stores

Online

Other Distribution Channels

B2B / Contractors / Builders

Contractors

Builders

By Geography

North America

United States

Canada

Mexico

South America

Brazil

Peru

Chile

Argentina

Rest of South America

Europe

United Kingdom

Germany

France

Spain

Italy

BENELUX (Belgium, Netherlands, Luxembourg)

NORDICS (Denmark, Finland, Iceland, Norway, Sweden)

Rest of Europe

Asia-Pacific

China

Japan

India

South Korea

Australia

South-East Asia

Rest of Asia-Pacific

Middle East & Africa

United Arab Emirates

Saudi Arabia

South Africa

Nigeria

Rest of Middle East & Africa

Key Players in the Vinyl Floor Covering Industry

Mohawk Industries

Tarkett SA

Shaw Industries Group

Armstrong World Industries

Gerflor Group

Explore more insights on vinyl floor covering competitive landscape: https://www.mordorintelligence.com/industry-reports/vinyl-floor-covering-market/companies?utm_source=abnewswire

Conclusion

The outlook for the vinyl floor covering market remains positive as remodeling activity, institutional demand, and rigid-core product adoption continue to support consistent expansion. While raw material price fluctuations and regulatory requirements present operational challenges, manufacturers are adjusting through supply chain diversification and improved product formulations.

The vinyl floor covering market forecast reflects steady demand across residential upgrades and commercial refurbishments. Product versatility, waterproof properties, and competitive pricing keep vinyl competitive against ceramic, laminate, and engineered wood. As sustainability requirements strengthen and construction cycles evolve, the vinyl floor covering industry is expected to maintain balanced growth supported by technological refinement, distribution expansion, and consistent consumer preference for resilient flooring solutions.

For more insights on the vinyl floor covering market, please visit the Mordor Intelligence page: https://www.mordorintelligence.com/industry-reports/vinyl-floor-covering-market?utm_source=abnewswire

Industry Related Reports:

DIY Home Improvement Market

The DIY home improvement market is estimated at USD 0.93 trillion in 2026 and is projected to reach USD 1.29 trillion by 2031, registering a CAGR of 6.87% during 2026–2031. Growth is driven by rising homeownership, increasing consumer preference for cost-effective renovations, expanding e-commerce distribution channels, and greater adoption of sustainable and smart home improvement solutions.

Get more insights: https://www.mordorintelligence.com/industry-reports/diy-home-improvement-market?utm_source=abnewswire

Kitchenware Market Share

The kitchenware market is estimated at USD 79.22 billion in 2026, up from USD 76.12 billion in 2025, and is forecast to reach USD 96.74 billion by 2031, growing at a CAGR of 4.08% during 2026–2031. Market expansion is supported by rising urbanization, growth in home cooking trends, increasing demand for premium and smart kitchen products, and expanding online retail penetration.

Get more insights: https://www.mordorintelligence.com/industry-reports/kitchenware-market?utm_source=abnewswire

Windows and Doors Market Size

The windows and doors market is expected to grow from USD 225.38 billion in 2026 to USD 278.36 billion by 2031, at a CAGR of 4.32% during the forecast period. Growth is fueled by rising construction activities in residential and commercial sectors, demand for energy-efficient and insulated products, urban infrastructure development, and renovation and remodeling trends worldwide.

Get more insights: https://www.mordorintelligence.com/industry-reports/windows-and-doors-market?utm_source=abnewswire

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana – 500032, India.

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email:Send Email
Phone: +1 617-765-2493
Address:11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/